{"entity":{"id":"nct05885464","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","aka":[],"tldr":"A phase 1/2 trial of BEAM-201 in non-Hodgkin lymphoma, run by Beam Therapeutics Inc., active and no longer recruiting.","summary":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) is a phase 1/2 interventional study registered as NCT05885464 by Beam Therapeutics Inc., with 5 participants enrolled, started 2023-05-25 and due to reach its primary completion in 2026-12. Interventions recorded: BEAM-201.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05885464","url":"https://clinicaltrials.gov/study/NCT05885464"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05885464","phase":"1/2","setting":"A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","sponsor":"Beam Therapeutics Inc.","enrolled":5,"outcomes":[]},"route":"/trials/nct05885464/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}